Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04960618 · ClinicalTrials.gov registry record · Phase 2
Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome
A Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 14
- Enrollment target
- 8
- Study locations
NCT04960618: Active Phase 2 study of Mycosis Fungoides and Sezary Syndrome, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04960618 is a Phase 2 study of Mycosis Fungoides and Sezary Syndrome that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 14 participants, below the 163-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (91% lower). The trial reports 8 study locations across 2 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04960618, a Phase 2 study of Mycosis Fungoides and Sezary Syndrome, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 14 participants
- Enrollment target
- 8
- Study locations
Study Summary
The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
Primary Outcome
Estimate overall response rate (ORR) using the composite global response criteria
Conditions Studied
Interventions
- DRUG Pembrolizumab
- DRUG Gemcitabine
Study Locations (8)
New York
- Memorial Sloan Kettering Suffolk - Commack (Limited Protocol Activities) - Commack
- Memorial Sloan Kettering Westchester (Limited Protocol Activities) - Harrison
- Memorial Sloan Kettering Cancer Center (All protocol activities) - New York
- Columbia University - New York
- Memorial Sloan Kettering Nassau (Limited protocol activities) - Uniondale
New Jersey
- Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities) - Basking Ridge
- Memorial Sloan Kettering Monmouth (Limited Protocol Activities) - Middletown
- Memorial Sloan Kettering Bergen (Limited Protocol Activities) - Montvale
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 14 participants |
| Start Date | 2021-10-01 |
| Est. Completion | 2027-07 |
| Phase | Phase 2 |
What the registry record for NCT04960618 still lists
NCT04960618 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 14 participants, a relatively small participant target, below the 163-participant average among 19 other Mycosis Fungoides trials with a reported enrollment target (91% lower).
The record links to 5 conditions, with Mycosis Fungoides appearing as the primary indexed condition, and to 2 interventions - of which Pembrolizumab is the first listed.
NCT04960618 lists 8 locations in 2 states (New York, New Jersey).
Frequently Asked Questions
What is clinical trial NCT04960618 about?
NCT04960618 is a clinical study titled "Pembrolizumab in Combination With Gemcitabine in People With Advanced Mycosis Fungoides or Sézary Syndrome". The purpose of this study is to find out whether the combination of pembrolizumab and gemcitabine is an effective treatment for mycosis fungoides and Sézary syndrome.
What is the current status of trial NCT04960618?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 14 participants. The study started on 2021-10-01. Estimated completion is 2027-07.
What conditions does trial NCT04960618 study?
This clinical trial studies the following conditions: Mycosis Fungoides, Sezary Syndrome, Mycosis Fungoides/Sezary Syndrome, Sézary, Advanced Mycosis Fungoides.
What interventions are being tested in trial NCT04960618?
The interventions under investigation include: Pembrolizumab (DRUG), Gemcitabine (DRUG).
Who is sponsoring clinical trial NCT04960618?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04960618 being conducted?
This trial has 8 study locations across New Jersey, New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Mycosis Fungoides
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04960618's enrollment target sits among peer trials
14 17th of 19 higher than 3 of 19 other Mycosis Fungoides trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Mycosis Fungoides trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Photopheresis in Early-stage Mycosis Fungoides
RECRUITING · Phase 2
-
Dosing of Brentuximab Vedotin for Mycosis Fungoides, Sezary Syndrome Patients
RECRUITING · Phase 2
-
Mogamulizumab + Low-Dose Total Skin Electron Beam Tx in Mycosis Fungoides & Sézary Syndrome
RECRUITING · Phase 2
-
Effectiveness of Concurrent Ultra-Low-Dose Total-Skin Electron Beam Therapy and Brentuximab Vedotin Given Quarterly Over 12 Months for Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
Ultra Low Dose Radiation Therapy in Treating Patients With Mycosis Fungoides
RECRUITING · Phase 2
-
SGN-35 in CD30-positive Lymphoproliferative Disorders (ALCL), Mycosis Fungoides (MF), and Extensive Lymphomatoid Papulosis (LyP)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02523092 · 14 participants · Phase 4
Use of CXCL9 as a Biomarker of Acthar Efficacy
- NCT04263285 · 14 participants · NA
Treatment of Depression Post-SCI
- NCT04743271 · 14 participants · NA
Food and Circadian Timing
- NCT05065671 · 14 participants · Phase 1
Microbiome Derived Metabolism and Pharmacokinetics
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT06358040 · started 2026-10 · NA
Opioid Dispenser for Microdiscectomy/Laminectomy